Condition 1: Multiple Sclerosis. Condition 2: Liver disease. Multiple sclerosis Other diseases of liver
Conditions
Interventions
Intervention 1: Intervention group: Patients with multiple sclerosis(RRMS) receiving Fingolimod alone For 6 months. Intervention 2: Intervention group: Patients with multiple sclerosis(RRMS) receiving
Sponsors
Research Council of Hamedan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who have had at least 3 weeks of onset of corticosteroid attack and received corticosteroids with liver enzymes following corticosteroid therapy. New Patients Receive Fingolimod Patients who are taking interferon and Glatiramer are advised to take the Fingolimod, provided they have no liver problem. Expanded Disability Status Scale below three.
Exclusion criteria
Exclusion criteria: Pregnant and lactating women Patients who are allergic to Silymarin Patients with previous history of tuberculosis, HIV, hepatitis and liver problems.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver complications. Timepoint: At the beginning of the study (before the intervention) and 30, 60, 90, 120, 150 and 180 days after taking Silymarin. Method of measurement: Malondialdehyde index with Ohkawa method- Total antioxidant capacity index with FRAP method- Measurement of protein thiol groups with Ellman's Reagent (DTNB). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Sara Ataei
Hamedan University of Medical Sciences
Outcome results
None listed